GLP's ⏱ Half-life: Approximately 5-6 days, supporting once-weekly administration.

Survodutide

Survodutide (BI 456906)

Buy from $119.99 →
Half-Life
Approximately 5-6 days, supporting once-weekly administration.
Mol. Weight
~4300 g/mol

What is Survodutide?

Survodutide represents the GLP-1/glucagon dual agonist approach to metabolic research — distinct from tirzepatide’s GLP-1/GIP mechanism. The glucagon component provides a unique advantage in liver fat mobilization, making it particularly promising for MASH/NASH research.

Research Applications

Currently in Phase 3 trials:

  • SYNCHRONIZE-1: Obesity/overweight
  • SYNCHRONIZE-2: MASH with liver fibrosis
  • Liver fat: Phase 2 showed near-complete resolution of hepatic steatosis
  • Body composition: Significant weight reduction with preserved lean mass

Dosage Information (Research Use)

Phase 2 titration: starting 0.3mg weekly, escalating through 0.9, 1.8, 2.7, to 4.8mg weekly over 16-20 weeks. Investigational — research use only.

Reconstitution & Handling

Standard BAC water reconstitution. Protect from light.

Half-Life & Pharmacokinetics

Approximately 5-6 days, supporting once-weekly administration.

Reported Observations in Literature

Phase 2 data: GI effects similar to GLP-1 class (nausea, vomiting, diarrhea). Dose-dependent. Heart rate increase observed in some subjects.

Key Research References

  • Ambery P, et al. “Efficacy and safety of survodutide in patients with MASH and fibrosis.” N Engl J Med. 2024

How Survodutide Works

Survodutide is a dual agonist targeting both GLP-1 and glucagon receptors. Unlike tirzepatide (GIP/GLP-1), survodutide pairs GLP-1 with glucagon receptor activation. The glucagon component drives hepatic lipid oxidation, thermogenesis, and increased energy expenditure — particularly effective for liver fat reduction. This GLP-1/glucagon combination produces both appetite suppression (GLP-1) and metabolic rate enhancement (glucagon), attacking energy balance from both sides.

Research Findings

Phase 2 data showed up to 19% body weight loss at 48 weeks and dramatic liver fat reduction (up to 87% relative reduction in MASH patients). Phase 3 SYNCHRONIZE program is underway for both obesity and MASH/NASH. Considered a strong competitor to tirzepatide for liver-focused metabolic research.

Dosage & Administration

Phase 2 titration: starting 0.3mg weekly, escalating through 0.9, 1.8, 2.7, to 4.8mg weekly over 16-20 weeks. Investigational — research use only.

Safety & Side Effects

Phase 2 data: GI effects similar to GLP-1 class (nausea, vomiting, diarrhea). Dose-dependent. Heart rate increase observed in some subjects.

Important: All safety information is derived from published research, primarily animal studies. No controlled human clinical trial data exists unless explicitly noted. This compound is sold for research purposes only.

Quick Facts

Sequence Modified dual agonist peptide with fatty acid acylation
Molecular Weight ~4300 g/mol
Half-Life Approximately 5-6 days, supporting once-weekly administration.
Available Sizes 5mg
Storage Lyophilized: -20°C. Reconstituted: 2-8°C, protect from light.

Key Research References

  • Ambery P, et al. "Efficacy and safety of survodutide in patients with MASH and fibrosis." N Engl J Med. 2024

Get Survodutide from SourcePeptides

Third-party tested • Research-grade purity • Fast US shipping

Shop Now →

Related Peptides

View all →
Setmelanotide
GLP's
FDA-approved melanocortin-4 receptor agonist for treating obesity caused by rare genetic disorders affecting the leptin-melanocortin pathway.
View Profile → Buy at SP →
Lixisenatide
GLP's
FDA-approved short-acting GLP-1 receptor agonist with unique postprandial glucose control properties.
View Profile → Buy at SP →
Pemvidutide
GLP's
GLP-1/glucagon dual agonist designed for better body composition — promoting fat loss while preserving muscle mass during weight…
View Profile → Buy at SP →